ISARIC has been committed to provide a wide breadth of COVID-19 clinical research resources since the beginning of the outbreak. These resources are fully adaptable and completely free to use
The tools below aim to cover a range of tiers, suitable for different needs:
- Data collection only
- Contributing clinical data
- Research protocols
- Guidance to start your study
- ISARIC’s affiliated studies
Tile subhead - Publications and Clinical data reports stemmed from the ISARIC COVID-19 clinical data platform.
Tile subhead - Collection of standardised clinical data.
Tile subhead - Modules to be used in addition to the Core or RAPID COVID-19 CRFs.
Tile subhead - Stand alone CRF for children and adolescents.
Tile subhead - Secure data capture system that standardises global data on COVID-19.
Tile subhead - Access ISARIC's data to generate and disseminate evidence.
Tile subhead - Data analysis frequently asked questions.
Tile subhead - Current data research analyses.
Tile subhead - Sites currently contributing to the clinical data platform.
Tile subhead - ISARIC/WHO protocol for standardised clinical data collection.
Tile subhead - Follow-up clinical data collection
Tile subhead - Survey for the follow-up of patients with confirmed COVID-19.
Tile subhead - Paediatric protocol and survey for the follow-up of COVID-19 patients.
Tile subhead - Guidance on the Global Clinical Characterisation Protocol.
Tile subhead - High quality rapid evidence synthesis for use in COVID-19 research.
Tile subhead - Clinical data collection with the aims of building a research or study
Visit this section to find ISARIC’s articles, studies and more.
On its 10th anniversary, University of Oxford’s ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) demonstrates the crucial role of global preparedness and collaboration for advancing knowledge on infectious disease pandemics.
Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds
Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on children hospitalised with COVID 19.
Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it is expensive and hard to source, and it has well-known toxicities.